Business Context and Reporting Period
This Form 8-K was filed by Hillstream BioPharma, Inc. (trading symbol: HILS) on October 27, 2022. The report addresses a regulatory notice received from the Nasdaq Stock Market, LLC regarding the company's compliance with continued listing standards. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice:
- Stock Price: The closing bid price of the Common Stock was below $1.00 per share for the last 30 consecutive business days prior to October 27, 2022.
Material Changes
The material event reported is the receipt of a formal notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. As of the filing date, the stock continues to trade on the Nasdaq Capital Market, but the company is now in a compliance period.
Outlook, Risks, and Management Commentary
Compliance Timeline: The company has been granted an initial period of 180 calendar days (until April 25, 2023) to regain compliance. To do so, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days within this window.
Future Actions: If compliance is not achieved by April 25, 2023, the company may qualify for a second 180-day compliance period. Failure to regain compliance during the second period could result in a delisting determination, which the company could appeal to a Nasdaq hearings panel.
Management Intent: Management intends to actively monitor the stock price and may consider implementing available options to regain compliance.
Risks: The filing highlights significant risks, including the possibility of failing to meet the minimum bid price requirement, the risk that Nasdaq may not grant relief from delisting, and the uncertainty of future stock performance. The company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the current closing bid price of HILS stock to assess progress toward the $1.00 threshold.
- Monitor the company's stock price for the required 10 consecutive days of compliance within the 180-day window.
- Review the company's most recent Form 10-K and 10-Q for detailed financial health and liquidity status, as this 8-K does not contain them.
- Watch for announcements regarding potential corporate actions (e.g., reverse stock splits) intended to address the bid price deficiency.
- Track the April 25, 2023 deadline for the initial compliance period.